Carrie Bourdow
Chief Executive Officer at TREVENA, INC.
Net worth: 43 442 $ as of 2024-03-30
Carrie Bourdow active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 2018-09-30 | - |
| Chairman | 2023-12-31 | - | |
| President | 2018-09-30 | - | |
| Director/Board Member | 2018-09-30 | 2023-12-31 | |
| Chief Operating Officer | 2018-02-01 | 2018-09-30 | |
| Corporate Officer/Principal | 2015-05-03 | 2018-02-01 |
Career history of Carrie Bourdow
Former positions of Carrie Bourdow
| Companies | Position | Start | End |
|---|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 2017-06-22 | 2023-07-29 |
| Independent Dir/Board Member | 2017-06-22 | 2023-07-29 | |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 2020-02-19 | 2023-03-06 |
| Independent Dir/Board Member | 2020-02-19 | 2023-03-06 | |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 2013-04-30 | 2015-04-30 |
Training of Carrie Bourdow
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Statistics
International
| United States | 6 |
| Ireland | 2 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Private companies | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Carrie Bourdow
- Experience
